Update on antifungal therapy.
Gigolashvili
T
T
Hahnemann University Hospital, Philadelphia, PA, USA.
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D000077336:Caspofungin; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D054714:Echinocandins; D006801:Humans; D055666:Lipopeptides; D008081:Liposomes; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology*; D009369:Neoplasms / Q000150:complications*; D009761:Nystatin / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D010455:Peptides; D010456:Peptides, Cyclic; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D065819:Voriconazole
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D004337:Drug Carriers; D054714:Echinocandins; D055666:Lipopeptides; D008081:Liposomes; D010455:Peptides; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D009761:Nystatin; C101425:posaconazole; D000077336:Caspofungin; D065819:Voriconazole